Quantcast
Last updated on April 17, 2014 at 10:34 EDT

Latest Auxilium Pharmaceuticals Inc. Stories

2012-12-27 08:24:23

MALVERN, Pa., Dec. 27, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted standard review status to its supplemental Biologics License Application (sBLA) for XIAFLEX(®) (collagenase clostridium histolyticum or CCH), a novel, in-office biologic therapy for the potential treatment of Peyronie's disease (PD). Under the Prescription Drug...

2012-12-13 16:24:19

LYNBROOK, N.Y., Dec. 13, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX® in Europe and Eurasia, today announced top-line 30-day data from the Phase Ib study of XIAFLEX for the potential treatment of adult patients with edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite, which is being conducted by BioSpecifics' partner...

2012-12-13 08:26:09

MALVERN, Pa., Dec. 13, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced top-line Day 30 data for collagenase clostridium histolyticum or CCH for the potential treatment, if approved by the U.S. Food and Drug Administration (FDA), of adult patients with edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite. The phase Ib study is a single site, open-label dose-escalation study that enrolled 99 women...

2012-12-07 08:24:09

MALVERN, Pa., Dec. 7, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Oppenheimer Annual Growth Conference to be held December 12-13, 2012 at the Waldorf Astoria Hotel in New York City. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 2:10 p.m. ET on Thursday, December 13, 2012. (Photo:...

2012-11-08 16:28:01

LYNBROOK, N.Y., Nov. 8, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced its financial results for the third quarter ended September 30, 2012 and provided a corporate update. "We are very happy with the ongoing clinical development progress for our XIAFLEX pipeline, including the recent submission of...

2012-11-07 16:28:17

LYNBROOK, N.Y., Nov. 7, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S., today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for XIAFLEX for the potential treatment of Peyronie's disease by BioSpecifics' partner Auxilium Pharmaceuticals, Inc. (Auxilium). If...

2012-11-07 08:27:07

MALVERN, Pa., Nov. 7, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for XIAFLEX(®) (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD). XIAFLEX for the treatment of PD was granted orphan drug...

2012-11-07 08:27:01

MALVERN, Pa., Nov. 7, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced financial results for the quarter ending on September 30, 2012. The Company also highlighted recent commercial, regulatory and clinical development progress in the third quarter of 2012 and has revised financial guidance for full year 2012. (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) For the quarter ended September 30, 2012,...

2012-11-01 07:30:45

MALVERN, Pa., Nov. 1, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the third quarter 2012 on Wednesday, November 7, 2012 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the third quarter 2012. The presentation slides to be used during the call will be available on the "For Investors" section of...

2012-09-05 10:26:05

LYNBROOK, N.Y., Sept. 5, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX(®) in Europe and Eurasia, today announced a safety update following 30 months of post-approval use in the U.S. of XIAFLEX for the treatment of adult Dupuytren's contracture patients with a palpable cord. As reported by BioSpecifics' strategic partner Auxilium...